Specific Aim 2. To investigate the pathogenic role of CB1R and iNOS in [ ] and test the therapeutic efficacy of dual CB1R/iNOS inhibition. Approaches for Aim 2: technical tools and experimental design will be the same as for Aim 1. Specific Aim 3: Screen and optimize additional CB1R/iNOS dual-target inhibitors as back-up compounds and lead optimization in animal models of scleroderma. Approaches for Aim 3: Scleroderma results in the failure of multiple organs including the liver and kidney. In view of the essential role of these organs in pharmacokinetics and drug metabolism, their pathological changes may alter the PK properties of therapeutic compounds. In order to optimize the druggable properties of dual-target compounds, their PK properties and metabolism need to be established for lead optimization.
Specific Aim 2. To improve HAART adherence among HIV-positive pregnant women. Phase II of this grant proposal is the implementation of the LIFT My HAART program. This program specific materials will be created using the data gathered during Phase I. LIFT My HAART will focus on the capacity building of Christian leaders at a grassroots level in Lusaka. LIFT My HAART will be implemented in partnership with CHAZ, MoH and selected Christian leaders, who will also be facilitating the trainings to their peers.
Specific Aim 2. We set rules for a neurological outcome variable based on expert movement disorder review of the exam data from specific aim 1. We leveraged study participation in an existing galactosemia cohort, and gathered any required missing genetic, biochemical, and other data. Parameters tested for possible association with neurological outcome included: age and gender of the volunteer, diagnosis type (newborn screening, once symptomatic), GALT enzyme activity level, GALT genotype. Study type We conducted a cross-sectional, single time point cohort study in a sample of convenience.
Examples of Specific Aim 2 in a sentence
In this situation, a Subdivision approval shall be conditioned that the third reading of the Land Use Bylaw amendment be given prior to endorsement of the subdivision.
Specific Aim 2: Assess whether H/L patients receiving DTM attain significantly improved patient-centered outcomes compared to COM, through a CER RCT.
Specific Aim #2: Analyze the effects of the introduction of the nutrition curriculum on child growth and nutritional status.
For Specific Aim 2, the same power calculations for Aim 1 apply; however, tests of indirect effects are exploratory, we will be powered to detect a moderate indirect effect (a*b = 0.25), using the same constraints as above.
Cape Air is heavily subsidized for seats each flight (Essential Air Service) which is a concern.
More Definitions of Specific Aim 2
Specific Aim 2. Determine whether infarct sizes are reduced and left ventricular pressure improved after an acute ischemic event in the absence of the FAN/nSMase signaling system by producing reversible cardiac infarcts using a currently available nSMase1 knockout mouse model. • Milestone 1: Establishment of breeding colony. • Milestone 2: Completion of surgeries and measurements of infarct size and left ventricular developed pressure (LVDP). Expectation of 20 – 50% decrease in infarct size and a significant increase in LVDP. The anticipated success of accomplishing these aims will demonstrate that the sphingomyelinase signaling system is a major participant in ischemia/reperfusion injury by validating nSMase1 and FAN as targets for drug discovery. This target validation will enable us to identifying small molecule inhibitors of this signaling system that can used in pre-clinical trials that we will propose in PHASE II. The ultimate goal of the research is to develop lead compounds that can be taken to Phase 1 Clinical Trials. The proposed work will form the basis of discovering novel medical therapeutics that will reduce the cell death associated with AMI and other acute ischemic events in the clinical setting. RESEARCH PLAN PROJECT II: Sphingolipids as Markers of Cardiac Ischemia
Specific Aim 2. To investigate the pathogenic role of[ ]and [ ]and test the therapeutic efficacy of dual [ ] inhibition. Approaches for Aim 2: technical tools and experimental design will be as for Aim 1. Specific Aim 3: Screen and optimize additional [ ]dual-target inhibitors as back-up compounds and lead optimization in animal models of scleroderma. PHS CRADA Agreement Ref. No. NIAAA 01638 MODEL ADOPTED June 18, 2009 Public Health Service Cooperative Research and Development Agreement Approaches for Aim 3: Scleroderma results in the failure of multiple organs including the liver and kidney. In view of the essential role of these organs in pharmacokinetics and drug metabolism, their pathological changes may alter the PK properties of therapeutic compounds. In order to optimize the druggable properties of dual-target compounds,[ ]
Specific Aim 2. To compare parental acceptability of management of their child’s acute otitis media, we will administer a questionnaire within 2 days of their child’s assessment, at an interim assessment if it occurs, and 4 weeks following the initial assessment. Hypothesis 2: Use of a smartphone otoscope by pediatric clinicians in a primary care practice to diagnose and manage children with otitis media will result in increased acceptability among parents of their child’s management, compared with the acceptability of parents whose children are managed by a provider using a conventional otoscope. Methods
Specific Aim 2. To perform therapeutic efficacy studies using nanocurcumin in a xenograft model of pancreatic cancer. Our laboratory has synthesized the first nanoparticle formulation of curcumin utilizing biodegradable polymeric components (Xxxxx et al, J Nanobiotechnology, 2007), and this formulation, as well as modifications thereof that enable systemic and oral delivery of curcumin, are embodied in the US Provisional Patent application Serial No. 60,866/516, filed on November 20th, 2006, and entitled "Biocompatible "smart" nanogels as carriers for hydrophobic drugs". This technology will be licensed to SignPath Pharma as defined under the appropriately reviewed and executed licensing agreement. We will conduct this sponsored research agreement in the PI’s laboratory with the intent of further characterizing nanocurcumin in vivo. In Specific Aim 1, we will test nanocurcumin administered by both oral and parenteral routes in order to determine an appropriate dosing schedule. All studies will be conducted in wild type CD1 mice. Curcumin bioavailability will be assessed by direct measurement of plasma curcumin levels using an HPLC assay (Heath et al, J Chromatogr B 783: 287; 2003); in a subset of mice, urine levels will also be measured. Standard pharmacokinetic assays for area under the curve (AUC) and maximal concentration (Cmax) will be performed in order to estimate bioavailability. In addition, pharmacodynamic assessment will be performed by measuring serum IL-6 levels, which we have demonstrated is reproducibly downregulated in peripheral blood lymphocytes upon curcumin exposure (Xxxxx et al, J Nanobiotechnology, 2007). Dose escalation studies will be performed in mice to evaluate potential toxicities, and identify a maximal tolerated dose (MTD). All studies will be performed with at least six mice per arm in order to obtain statistically significant differences. Comprehensive necropsy will be performed and visceral organs evaluated histologically for any evidence of toxicity from the curcumin-nanoparticle formulation. In Specific Aim 2, we will evaluate the therapeutic efficacy of nanocurcumin in a pancreatic cancer xenograft model. Briefly, we will generate subcutaneous xenografts in athymic mice that will be randomized to receive vehicle alone, nanocurcumin, gemcitabine (standard of care), and the combination. We postulate that the combination of nanocurcumin and gemcitabine will demonstrate enhance efficacy to single agent therapy. Xenografts will be treated for...
Specific Aim 2. Refine BH treatment strategies in ex vivo prostatic tissue. Based on the acoustic characterization results and the derating approach developed by our team for predicting in situ parameters of nonlinear ultrasound field (Khokhlova 2011), we will design BH treatment protocols and test them in phantom gels mimicking prostate and ex vivo canine prostate tissue. These experiments will identify an optimal treatment strategy for concurrent in vivo studies and inform development of future treatment planning software. Specifically, we will identify the necessary power, pulsing, and scanning strategies. Tests will also be performed in ex vivo bovine liver due to its unique composition of glandular and fibrous regions (allowing extrapolation to mixed fibrous and glandular hyperplasia seen in BPH). Dose response, i.e. the number of BH pulses delivered per focal spot necessary for complete tissue fractionation will be established. The strategy that provides most rapid and uniform ablation by the BH device will then be used in the in vivo experiments. Mechanically ablated volumes in ex vivo canine prostate tissue will be evaluated grossly and processed for histology.
Specific Aim 2. To investigate the pathogenic role of[ ]and [ ]and test the therapeutic efficacy of dual [ ] inhibition. Approaches for Aim 2: technical tools and experimental design will be as for Aim 1. Specific Aim 3: Screen and optimize additional [ ]dual-target inhibitors as back-up compounds and lead optimization in animal models of scleroderma. PHS CRADA Agreement Ref. No. NIAAA 01638 MODEL ADOPTED June 18, 2009 PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED AND ARE SUBJECT TO A CONFIDENTIAL INFORMATION REQUEST FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Public Health Service Cooperative Research and Development Agreement Approaches for Aim 3: Scleroderma results in the failure of multiple organs including the liver and kidney. In view of the essential role of these organs in pharmacokinetics and drug metabolism, their pathological changes may alter the PK properties of therapeutic compounds. In order to optimize the druggable properties of dual-target compounds,[ ]
Specific Aim 2. To create, during the course of a one year, school-based telehealth pilot asthma program, a sustainable eco-education and environmental health curriculum at the eight participating schools.